ABSTRACT
Aims: Objective of the study was to investigate the wound contraction and antiinflammatory activity of the 50% ethanolic extract of Fumaria indica (Hausskn.) Pugsley (Fumariaceae) by excision wound model and estimation of pro-inflammatory and antiinflammatory cytokines. Study Design: Prospective. Place and Duration of Study: Department of Pharmacognosy and Ethnopharmacology, CSIR-National Botanical Research Institute, Lucknow, India. December 2012 to May 2013. Methodology: Dried powdered whole plant of Fumaria indica was extracted with 50% ethanolic extract. The extract was subjected to HPTLC fingerprinting, DPPH free radical scavenging and antibacterial activities. Further, 10% F. indica ointment was tested for its wound contraction, pro-inflammatory and anti-inflammatory potentials. Results: The 50% ethanolic extract showed presence of ellagic acid, ferulic acid andquercetin. The IC50 was 0.11mg/mL and significant antibacterial activity was observed against S. aureus and E. coli. The 10% F. indica ointment applied topically to the wound area reducedits size from 500 mm2 to 40 mm2 by the end of 9th day. These results were comparable to the effect of 0.2% nitrofurazone. The extract further showed a reduction in the release of pro-inflammatory cytokines (TNFα and IL-6) and an increase in antiinflammatory cytokine IL-10.
ABSTRACT
Background & objectives: As the dosages recommended for children are based on weight, empirical and derived by extrapolation from the studies in adults, pyrazinamide (PZA) pharmacokinetics in children is likely to be different from adults. Limited information exists regarding the pharmacokinetics of PZA in paediatric patients of primary progressive disease (PPD) of lungs. This study aims to look at the changed pharmacokinetics of pyrazinamide in children with PPD of lungs by using reverse phase high-pressure liquid chromatography (HPLC). Methods: A total of 40 children (age range 5 to 13 yr) of PPD were receiving pyrazinamide (30 mg/kg/day). On 11th day of short course antitubercular therapy, blood samples (two per day from 11th to 13th day) were collected at 0 h (pre-dose), 1, 2, 3, 4, 8 and 24 h after pyrazinamide administration and concentration of pyrazinamide was estimated by reverse phase high-pressure liquid chromatography. The mean peak serum concentration, the time to reach mean peak serum concentration, total clearance, concentration at time zero, volume of distribution, terminal elimination rate constant, elimination half-life, total area under serum concentration-time curve were measured. Results: The mean serum concentrations of pyrazinamide were found higher than its minimum inhibitory concentration (20 μg/ml) required to inhibit the growth of tubercle bacilli from 1 to 8 h continuously. Interpretation & conclusions: Our results suggest that a dose of 30 mg/kg/day achieves much higher concentration of pyrazinamide as compared to its minimum inhibitory concentration (20 μg/ml). Therefore, lowering of pyrazinamide dosage is suggested in children for better patient compliance along with reduction in cost, side-effects and toxicity without compromising its efficacy.
ABSTRACT
BACKGROUND & OBJECTIVE: As the dosages recommended for children are based on weight, empirical and derived by extrapolation from the studies in adults, pyrazinamide (PZA) pharmacokinetics in children is likely to be different from adults. Limited information exists regarding the pharmacokinetics of PZA in paediatric patients of primary progressive disease (PPD) of lungs. This study aims to look at the changed pharmacokinetics of pyrazinamide in children with PPD of lungs by using reverse phase high-pressure liquid chromatography (HPLC). METHODS: A total of 40 children (age range 5 to 13 yr) of PPD were receiving pyrazinamide (30 mg/kg/day). On 11(th) day of short course antitubercular therapy, blood samples (two per day from 11(th) to 13(th) day) were collected at 0 h (pre-dose), 1, 2, 3, 4, 8 and 24 h after pyrazinamide administration and concentration of pyrazinamide was estimated by reverse phase high-pressure liquid chromatography. The mean peak serum concentration, the time to reach mean peak serum concentration, total clearance, concentration at time zero, volume of distribution, terminal elimination rate constant, elimination half-life, total area under serum concentration-time curve were measured. RESULTS: The mean serum concentrations of pyrazinamide were found higher than its minimum inhibitory concentration (20 microg/ml) required to inhibit the growth of tubercle bacilli from 1 to 8 h continuously. INTERPRETATION & CONCLUSION: Our results suggest that a dose of 30 mg/kg/day achieves much higher concentration of pyrazinamide as compared to its minimum inhibitory concentration (20 microg/ml). Therefore, lowering of pyrazinamide dosage is suggested in children for better patient compliance along with reduction in cost, side-effects and toxicity without compromising its efficacy.